Drugs / CC-115
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02833883 | Jul 2016 → Jan 2023 | castration-resistant prostate carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01353625 | Apr 2011 → Mar 2021 | Ewing sarcoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, glioblastoma, head and neck squamous cell carcinoma +2 | Celgene Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02977780 | Feb 2017 → Feb 2028 expected | glioblastoma | Patrick Wen, MD | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01353625 ↗ |
| Action | Inhibit | “CC-115, a dual inhibitor of mammalian target of rapamycin (mTOR) kinase and DNA-dependent protein kinase.” PMID 31853198 ↗ Dec 20192“Serine/threonine-protein kinase mTOR inhibitor” CHEMBL3586573 ↗ “DNA-dependent protein kinase inhibitor” CHEMBL3586573 ↗ |
| Modality | Small molecule | — CHEMBL3586573 ↗ |
| Route | Oral | “Dose level starts with 0.5mg daily by mouth” NCT01353625 ↗ |
| Target | MTOR | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL3586573 ↗ |
| Target | PRKDC | “DNA-dependent protein kinase inhibitor” CHEMBL3586573 ↗ |